PDCD1 and acute kidney injury: Moreover, a recent meta-analysis of randomized clinical trials demonstrated that combined use of anti-PD-1 or PD-L1 antibodies with chemotherapy increased the risk of severe acute kidney injury and the composite of all severe acute kidney adverse events (28, 29).